Paul O’Connor

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Paul O’Connor, Massimo Filippi, Barry G.W. Arnason et al. · The Lancet Neurology · 2009 · 402 citations · Full text

Relapsing-remitting Multiple Sclerosis, Neurological Disorder, Multicentre Study +8

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Patrick Vermersch, Anna Członkowska, Luigi ME Grimaldi et al. · Multiple Sclerosis Journal · 2013 · 348 citations · Full text

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

V. Devonshire, Eva Havrdová, Ernst W. Radue et al. · The Lancet Neurology · 2012 · 180 citations

Placebo-controlled Freedoms Study, Disease Progression, Neurological Disorder +9

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

Kathryn C. Fitzgerald, Kassandra L. Munger, Karl Köchert et al. · JAMA Neurology · 2015 · 165 citations

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

Catherine M. Dalton, Katherine Miszkiel, Gareth J. Barker et al. · Journal of Neurology · 2004 · 126 citations

Neurobiology Of Disease, T1 Hypointense Lesions, Neurological Disorder +8